Evidence map›Paper›PMID 39935342›Full record

ArticleNanomedicine (London, England)2025

Dopamine stabilized in ultra-nanoreservoirs for controlled delivery in parkinson's disease.

Francisco J Padilla-Godínez, Tessy López-Goerne, Evelyn Y Calvillo-Muñoz, Mayra Angélica Álvarez-Lemus, Juan Navarrete-Bolaños, Omar Collazo-Navarrete, Obed R Lora-Marín, María-Del-Carmen Cárdenas-Aguayo, Myrian Velasco, Magdalena Guerra-Crespo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanomedicine (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Francisco J Padilla-GodínezRegenerative Medicine Laboratory, Department of Physiology, Faculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico.
Tessy López-GoerneLaboratory of Nanotechnology and Nanomedicine, Department of Health Care, Metropolitan Autonomous University, Mexico City, Mexico.
Evelyn Y Calvillo-MuñozCenter for Research and Technological Innovation, National Polytechnic Institute, Mexico City, Mexico.
Mayra Angélica Álvarez-LemusJuarez Autonomous University of Tabasco, Villahermosa, Tabasco, Mexico.
Juan Navarrete-BolañosMexican Petroleum Institute, Mexico City, Mexico.
Omar Collazo-NavarreteNational Laboratory of Genomic Resources, Institute of Biomedical Research, National Autonomous University of Mexico, Mexico City, Mexico.
Obed R Lora-MarínLaboratory of Cellular Reprogramming, Department of Physiology, Faculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico.
María-Del-Carmen Cárdenas-AguayoLaboratory of Cellular Reprogramming, Department of Physiology, Faculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico.
Myrian VelascoNeurosciences Division, Cell Physiology Institute, National Autonomous University of Mexico, Mexico City, Mexico.
Magdalena Guerra-CrespoRegenerative Medicine Laboratory, Department of Physiology, Faculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsParkinson's disease (PD) is a neurodegenerative disorder caused by the progressive degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to impaired dopamine (DA) signaling and motor control. Intermittent dosing of current DA precursors results in side effects, prompting research into controlled drug release mechanisms for sustained and targeted delivery of DA. MATERIALS &

methodsIn this work, we stabilized DA within a nanostructured silicate matrix (nanoreservoir) using the sol-gel method. We examined the physicochemical properties, kinetics of drug release, and biocompatibility in dopaminergic neurons and fibroblasts.

resultsThe optimized synthesis method allowed for the stabilization of DA by preventing its oxidation. The physicochemical and controlled release analysis showed a direct relationship between the mesoporous structure, interaction of the DA with the matrix, and the release kinetics followed, proving the possibility to modify the rate of release by adjusting the synthesis parameters. Furthermore, the nanoreservoirs were biocompatible with dopaminergic neurons and fibroblasts

conclusionsThe research sets the stage for potential

Indexed as

DopamineNanostructuresParkinson DiseaseAnimalsDelayed-Action PreparationsDopaminergic NeuronsDrug Delivery SystemsDrug LiberationFibroblastsHumansSilicatesDelayed-Action PreparationsDopamineSilicatesdopamineNanoreservoirparkinson’s diseaserelease kineticssilicates

Identifiers

PMID39935342
PMCPMC11881884

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.